Aptus Pharma SME IPO Continues to Witness Strong Investor Interest on Day 2

Ahmedabad, September 24, 2025 – The SME Initial Public Offering (IPO) of Aptus Pharma Limited is seeing a healthy investor appetite. The issue was subscribed 2.89 times in total by late afternoon on Day 2 of bidding. High-Net-Worth Individuals (HNIs) and retail investors are spearheading this strong participation.

Aptus Pharma SME IPO Day 2 Subscription Highlights

Taking a look at the overall subscription, the ₹13.02 crore public offering has been subscribed a good 2.89 times.

• Retail Investor Strength: Retail Individual Investors (RIIs) are showing a strong interest, with their reserved portion being oversubscribed 3.71 times.
• HNI Segment Leads: Non-Institutional Investors (NIIs) have been extremely keen, bidding for 4.30 times the allotted shares. Of particular interest is the bids over the ₹10 lakh bracket, which has recorded exceptional demand, oversubscribing 6.94 times.
• QIB Participation: Qualified Institutional Buyers (QIBs) have not yet put in any bids, something that will be watched keenly on the last day.

Aptus Pharma SME IPO Pricing Details

Investor preference can be seen in the bidding trends with a strong penchant for the higher end of the price band of ₹65 to ₹70. The firm is a well-established entity in the marketing and distribution of finished pharmaceutical formulations.

Aptus Pharma SME IPO Anchor Investor Details

Before the public issue, Aptus Pharma raised ₹3.70 crore from its anchor book on September 22, 2025, by issuing 5,28,000 shares at the cap price of ₹70 per share. The key anchor investors were 31 Degrees North Fund – Fund I, Eminence Global Fund PCC – Eubilía Capital Partners Fund I, and Zeal Global Opportunities Fund.

Aptus Pharma SME IPO an entirely fresh issue of 18.6 lakh equity shares, closes for subscription tomorrow, September 25, 2025. The final bidding day will be crucial in identifying the overall level of oversubscription, particularly in view of the anticipated participation of QIBs. The listing of shares is provisionally pending on the BSE SME platform on September 30, 2025.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations